Last reviewed · How we verify

NCT06945796

ACT-ED: Accessibility and Feasibility of an Acceptance and Commitment Therapy (ACT)-Based Eating Disorder Prevention Program

Completed NA Last updated 10 June 2025
What this trial tests

NA trial testing ACT based eating disorder prevention program in Eating Disorders Symptoms in 5 participants. Completed in 2 February 2025.

Timeline
18 November 2024
Primary endpoint
2 February 2025
2 February 2025

Quick facts

Lead sponsorIbn Haldun University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment5
Start date18 November 2024
Primary completion2 February 2025
Estimated completion2 February 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ibn Haldun University

Who can join

18 and older, female only, with Eating Disorders Symptoms or Eating Pathology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to investigate the accessibility and feasibility of an online group prevention program developed for women at risk for eating disorders. Also, to conduct a preliminary analysis of treatment efficacy. The main questions it aims to answer are: Does ACT-ED an acceptable intervention for women at risk for eating disorders? Does intervention result in reduced eating pathology? Participants will: Join the online, 4-session ACT-based group program Fill the measures at Pre-test, post-test and follow-up assessment

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Eating Disorders Symptoms

Currently open trials in the same condition.

Other Ibn Haldun University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06945796.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing